CADTH | Evidence Driven
CADTH | Evidence Driven

Tamper-Resistant Oxycodone: A Review of the Clinical Evidence and Cost-effectiveness

Details

Files
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC0675-000

Question


  1. What is the clinical evidence on the harms associated with non-tamper-resistant oxycodone formulations in adults, including misuse and abuse?

  2. What is the clinical evidence on the harms associated with tamper-resistant oxycodone formulations in adults, including misuse and abuse?

  3. What is the evidence for the reduction of misuse, abuse, and related harms with tamper-resistant oxycodone compared with non-tamper resistant formulations?

  4. What is the cost-effectiveness of tamper-resistant oxycodone?

  5. What are the evidence-based guidelines for the use of tamper-resistant oxycodone?


Key Message

Evidence from RCTs and observational studies suggest that tamper-resistant oxycodone has the potential to reduce misuse, abuse and their associated harms. Tamper-resistant oxycodone formulations may also decrease healthcare costs associated with the misuse and abuse of oxycodone.


Files

Tamper-Resistant Oxycodone: A Review of the Clinical Evidence and Cost-effectiveness Rapid Response June 25, 2015 View PDF
Last Updated : June 25, 2015